Biotech | October 27, 2025
Lilly buys Adverum for its phase 3-stage eye disease gene therapy
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
